Department of Biochemistry and Molecular and Structural Biology, Jozef Stefan Institute, Ljubljana, Slovenia.
Department of Biology, Institute of Molecular Systems Biology, ETH Zürich, Zürich, Switzerland.
Expert Opin Ther Targets. 2020 Jun;24(6):573-588. doi: 10.1080/14728222.2020.1746765. Epub 2020 Apr 6.
: Cysteine cathepsins are involved in the development and progression of numerous inflammation-associated diseases such as cancer, arthritis, bone and immune disorders. Consequently, there is a drive to progress research efforts focused on cathepsin use in diagnostics and as therapeutic targets in disease.: This review discusses the potential of cysteine cathepsins as therapeutic targets in inflammation-associated diseases and recent advances in preclinical and clinical research. We describe direct targeting of cathepsins for treatment purposes and their indirect use in diagnostics.: The targeting of cysteine cathepsins has not translated into the clinic; this failure is attributed to off- and on-target side effects and/or the lack of companion biomarkers. This field now embraces developments in diagnostic imaging, the activation of prodrugs and antibody-drug conjugates for targeted drug delivery. The future lies in improved molecular tools and therapeutic concepts that will find a wide spectrum of uses in diagnostic and therapeutic applications.
半胱氨酸组织蛋白酶参与许多与炎症相关的疾病的发展和进展,如癌症、关节炎、骨骼和免疫紊乱。因此,人们致力于推进研究工作,重点关注组织蛋白酶在疾病诊断和治疗靶点中的应用。
本综述讨论了半胱氨酸组织蛋白酶作为炎症相关疾病治疗靶点的潜力,以及临床前和临床研究的最新进展。我们描述了直接针对组织蛋白酶进行治疗的方法,以及间接用于诊断的方法。
针对半胱氨酸组织蛋白酶的靶向治疗尚未转化为临床应用;这种失败归因于脱靶和靶外副作用,和/或缺乏伴随生物标志物。该领域现在接受了诊断成像、前体药物激活和抗体药物偶联物的靶向药物递送方面的进展。未来在于改进分子工具和治疗概念,这些将在诊断和治疗应用中得到广泛应用。